Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 6/20 | 0.55 |
| ▸ | HTR7 | P34969 | 10/20 | 0.53 |
| ▸ | HTR2B | P41595 | 10/20 | 0.53 |
| ▸ | HTR3A | P46098 | 10/20 | 0.53 |
| ▸ | HTR1A | P08908 | 9/20 | 0.53 |
| ▸ | HTR6 | P50406 | 7/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | HTR1D | P28221 | 7/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HTR1B | P28222 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20817850 | 0.94 | TRPC5 (0.58) | TRPC5HTR7HTR2BHTR3AHTR1A | |
| SCHEMBL20831707 | 0.82 | HTR7 (0.57) | HTR7HTR2BHTR3AHTR1AHTR6 | |
| SCHEMBL25694464 | 0.77 | TRPC5 (0.60) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL20831227 | 0.77 | POLB (0.68) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL25695016 | 0.75 | HTR7 (0.54) | TRPC5HTR7HTR2BHTR3AHTR1A | |
| SCHEMBL14081025 | 0.75 | POLB (0.76) | TRPC5HTR7HTR2BHTR3AHTR1A | |
| SCHEMBL20818647 | 0.74 | TRPC5 (0.50) | TRPC5POLBALDH1A1HTR2CTIPARP | |
| Hydrochloric Acid SCHEMBL20818166 | 0.74 | POLB (0.73) | TRPC5HTR7HTR2BHTR3AHTR1A | |
| SCHEMBL25275764 | 0.73 | TRPC5 (0.60) | TRPC5POLBALDH1A1TIPARP | |
| SCHEMBL20831218 | 0.72 | TRPC5 (0.55) | TRPC5POLBALDH1A1TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| EP-3684364-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | TRPC5 1439/4885HTR7 269/4885HTR2B 380/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | TRPC5 1439/4885HTR7 269/4885HTR2B 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.